Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2022 | May 06, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001091596 | |
Entity Registrant Name | Nuo Therapeutics, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2022 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 000-28443 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 23-3011702 | |
Entity Address, Address Line One | 8285 El Rio, Suite 190 | |
Entity Address, City or Town | Houston | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 77054 | |
City Area Code | 346 | |
Local Phone Number | 396-4770 | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 40,674,205 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
ASSETS | ||
Cash and cash equivalents | $ 665,391 | $ 1,414,569 |
Other receivables | 64,000 | 0 |
Inventory, net | 94,642 | 0 |
Prepaid expenses and other current assets | 138,296 | 51,349 |
Total current assets | 962,329 | 1,465,918 |
Property and equipment, net | 11,848 | 0 |
Operating lease right of use assets | 84,023 | 0 |
Total assets | 1,058,200 | 1,465,918 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Common stock; $0.0001 par value, 100,000,000 shares authorized, 37,124,205 shares issued and outstanding | 3,713 | 3,713 |
Additional paid-in capital | 24,491,958 | 24,382,195 |
Accumulated deficit | (23,968,449) | (23,593,069) |
Total stockholders' equity | 527,222 | 792,839 |
Total liabilities and stockholders' equity | 1,058,200 | 1,465,918 |
Current liabilities | ||
Accounts payable | 423,793 | 526,557 |
Accrued liabilities | 31,128 | 146,522 |
Current portion of operating lease liabilities | 20,826 | 0 |
Total current liabilities | 475,747 | 673,079 |
Non-current portion of operating lease liabilities | 55,230 | 0 |
Total liabilities | 530,978 | 673,079 |
Commitments and contingencies (Note 7) |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 37,124,205 | 37,124,205 |
Common stock, shares outstanding (in shares) | 37,124,205 | 37,124,205 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenue: | ||
Revenue | $ 0 | $ 0 |
Costs of sales | 0 | 0 |
Gross profit (loss) | 0 | 0 |
Operating expenses | ||
Selling, general and administrative | 521,818 | 5,721 |
Total operating expenses | 521,818 | 5,721 |
Loss from operations | (521,818) | (5,721) |
Other income (expense) | ||
Interest expense, net | 0 | 0 |
Other income | 146,438 | 0 |
Total other income | 146,438 | 0 |
Net loss | $ (375,380) | $ (5,721) |
Basic and diluted (in dollars per share) | $ (0.01) | $ 0 |
Basic and diluted (in shares) | 37,124,205 | 30,258,744 |
Product [Member] | ||
Revenue: | ||
Revenue | $ 0 | $ 0 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 30,258,744 | |||
Balance at Dec. 31, 2020 | $ 3,026 | $ 22,995,854 | $ (23,502,399) | $ (503,519) |
Net loss | $ 0 | (5,721) | (5,721) | |
Balance (in shares) at Mar. 31, 2021 | 30,258,744 | |||
Balance at Mar. 31, 2021 | $ 3,026 | 22,995,854 | (23,508,120) | (509,240) |
Balance (in shares) at Dec. 31, 2021 | 37,124,205 | |||
Balance at Dec. 31, 2021 | $ 3,713 | 24,382,195 | (23,593,069) | 792,839 |
Issuance of options to settle related party compensation liabilities | 103,333 | 103,333 | ||
Stock compensation expense | 6,430 | 6,430 | ||
Net loss | (375,380) | (375,380) | ||
Balance (in shares) at Mar. 31, 2022 | 37,124,205 | |||
Balance at Mar. 31, 2022 | $ 3,713 | $ 24,491,958 | $ (23,968,449) | $ 527,222 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 36 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net loss | $ (375,380) | $ (5,721) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Stock-based compensation | 6,430 | 0 | |
Gain on settlement of accounts payable | (146,438) | 0 | |
Amortization of operating lease right of use assets | 5,289 | 0 | |
Changes in operating assets and liabilities: | |||
Other receivables | (64,000) | 0 | |
Inventory, net | (94,642) | 0 | |
Prepaid expenses and other current assets | (86,947) | 0 | |
Accounts payable | 43,674 | 1,553 | |
Accrued liabilities | (12,061) | 0 | |
Operating lease liabilities | (13,255) | 0 | |
Net cash used in operating activities | 737,330 | 4,168 | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Purchases of property and equipment | (11,848) | 0 | |
Net cash used in investing activities | (11,848) | 0 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Net cash provided by financing activities | 0 | 0 | $ 1,900,000 |
Net decrease in cash and cash equivalents | (749,178) | (4,168) | |
Cash and cash equivalents, beginning of period | 1,414,569 | 161,432 | |
Cash and cash equivalents, end of period | 665,391 | 157,264 | $ 1,414,569 |
Supplemental information | |||
Interest expense | 0 | 0 | |
Income taxes | 0 | 0 | |
Non-cash investing and financing transactions | |||
Issuance of options to settle accrued compensation liabilities | 103,333 | 0 | |
ROU assets and lease liabilities established at inception of lease | $ 89,312 | $ 0 |
Note 1 - Description of Busines
Note 1 - Description of Business | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | Note 1 Description of Business Description of Business Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a Delaware corporation organized in 1998 1999, 2000, 2001, 11 2002 September 2007, 510 April 2010, February 2012, 2014, 2016, 11. May 1, 2019, April 2021, October 2021 May 2022. Impact of COVID- 19 On March 11, 2020, 19 The extent to which COVID- 19 may not The Company has not March 31, 2022 19. |
Note 2 - Recapitalization
Note 2 - Recapitalization | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Recapitalization [Text Block] | Note 2 Recapitalization In anticipation of returning to operational status, the Company undertook several financing transactions during 2019 2021 2018 In September 2018, two “2018 two The notes had an original maturity date nine June 17, 2019). 2018 six two 25 not Throughout the first three 2019, 2018 September 17, 2019. 2018 July 31, 2019. In December 2019, 2018 2018 February 10, 2020. December 10, 2019 February 5, 2020 2020 2019 In November December 2019, “2019 2018 On September 1, 2020, 2019 2019 October 2020 ( 2020 2020 In October 2020 2019 2019 ● Deerfield exchanged its Series A Preferred Stock for 2.7 million shares of Common Stock – note that the Series A Preferred Stock did not ● The Noteholders converted $305,000 of principal and $30,400 of accrued and unpaid interest of their Senior Secured Notes (the Company was in default at the time of the conversion) ● The Noteholders agreed to purchase 487,500 shares of Common Stock for gross proceeds of $195,000 in cash. ● The Noteholders received warrants to purchase 3,977,961 shares of Common Stock at $0.40 per share. ● The Noteholders agreed to cancel the warrants originally issued with the 2019 The settlement of the Series A Preferred Stock was accounted for at fair value. The Company recognized a deemed dividend (contribution) resulting from the gain on the cancellation of its equity classified preferred stock, calculated as the difference between the fair value of the consideration transferred and the carrying value of the preferred stock. In addition, Lawrence S. Atinsky, the Deerfield Investors’ representative on the Company’s board, resigned and the number of Company directors was reduced to four. Outstanding options to purchase common stock held by Mr. Atinsky as of the Effective Date were forfeited. The settlement of the 2019 2019 2019 As part of the Recapitalization, the Company granted to each of three 3 2021 In December 2021, January 31, 2022 ( December 30, 2021. See Notes 5 6 |
Note 3 - Liquidity and Summary
Note 3 - Liquidity and Summary of Significant Accounting Principles | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 3 Liquidity and Summary of Significant Accounting Principles Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 2021, 2020 2019, December 2021, March 31, 2022, April 29, 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of March 31, 2022, May 6, 2022, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. As a result of the closing of the private placement for proceeds of $3,500,000 on April 29, 2022, one Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, they do not December 31, 2021, not may not 10 December 31, 2021. The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not Credit Concentration We had no April 2019 three March 31, 2022 2021 May 2022. Historically, we used single suppliers for several components of the Aurix® product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no one not Cash and Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three Accounts Receivables, net We expect to generate accounts receivables from the sale of our products. We will provide for an allowance against receivables for estimated losses that may not March 31, 2022 2021 no Other Receivables The other receivable at March 31, 2022 March 31, 2022. Inventory, net Our inventory is produced by third first first 18 two As of March 31, 2022, We will provide for an allowance against inventory for estimated losses that may Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six one three April 2022. March 31, 2022, March 2022 Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not As more fully described above, we had no revenues in the three March 31, 2022 2021. Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities are based on the equally weighted average historical volatility from five three March 31, 2022 2021 2022 2021 Risk free rate 1.65 % 0.33 % Weighted average expected years until exercise 5-6 5 Expected stock volatility 100 % 100 % Dividend yield - - The Company elected to account for forfeitures of stock-based awards as they occur. Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2022 2021. Basic and Diluted Earnings (Loss) per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none All of the Company’s outstanding stock options and warrants were considered anti-dilutive for the three March 31, 2022 2021. Three months ended March 31, 2022 Three months ended March 31, 2021 Shares underlying: Common stock options 2,536,667 1,355,001 Stock purchase warrants 233,333 13,278,794 2,770,000 14,633,795 Recently Adopted Accounting Standards In August 2020, 2020 06 December 15, 2023, We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not |
Note 4 - Property and Equipment
Note 4 - Property and Equipment | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | Note 4 Property and Equipment Property and equipment, net consisted of the following: March 31, 2022 December 31, 2021 Medical equipment $ 387,665 $ 387,665 Office equipment 3,243 - Warehouse/production equipment 8,605 - 399,513 387,665 Less accumulated depreciation and amortization (387,665 ) (387,665 ) Property and equipment, net $ 11,848 $ - There was no depreciation expense of property and equipment for the three March 31, 2022 2021. None three March 31, 2022 2021. |
Note 5 - Stock Purchase Warrant
Note 5 - Stock Purchase Warrants | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Stock Purchase Warrants [Text Block] | Note 5 Stock Purchase Warrants The following schedule reflects outstanding stock purchase warrants activities as of March 31, 2022 2021: Description March 31, 2022 March 31, 2021 May 2016 warrants - 6,180,000 2018 Convertible Notes warrants 233,333 233,333 2020 Replacement warrants - 3,977,961 2020 Compensatory warrants - 2,887,500 Total 233,333 13,278,794 As part of the May 2016 May 5, 2021 The 2018 March 31, 2022 In connection with the Recapitalization and the conversion of the 2019 five In connection with the Recapitalization and to compensate certain individuals for services performed in maintaining the Company’s viability, the Company issued stock purchase warrants to acquire 2,887,500 shares of the Company’s common stock. The warrants had an exercise price of $0.40, a term of five In connection with the Modification, the Company induced the exercise of existing stock purchase warrants to acquire 6,865,461 shares of the Company’s common stock by reducing the exercise price from $0.40 to $0.20 and requiring exercise by a certain date. All warrants were exercised by December 31, 2021 |
Note 6 - Equity and Stock-based
Note 6 - Equity and Stock-based Compensation | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 6 Equity and Stock-Based Compensation Under the Second Amended and Restated Certificate of Incorporation, the Company has the authority to issue a total of 101,000,000 shares of capital stock, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, par value $0.0001 per share, which will have such rights, powers and preferences as the Board of Directors shall determine. Stock-Based Compensation In July 2016, 2016 “2016 August 4, 2016, first January 1, 2017) six may not November 21, 2016, 2016 March 4, 2022, 2016 April 21, 2022, March 2022 2016 June 6, 2022. A summary of stock option activity under the 2016 three March 31, 2022 Stock Options 2016 Omnibus Plan Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 1,181,666 $ 0.69 10.00 Exercised - $ - - Forfeited or expired - $ - - Outstanding at March 31, 2022 2,536,667 $ 0.60 6.58 Exercisable at March 31, 2022 2,103,334 $ 0.57 5.89 There were 1,181,666 stock options granted under the 2016 three March 31, 2022 third three March 31, 2022. March 31, 2022, For the three March 31, 2022, three March 31, 2021. |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 7 Commitments and Contingencies Lease Agreements January 2022, December 31, 2024. Operating lease ROU assets are included in right of use assets in the Company's consolidated balance sheet as of March 31, 2022. The lease was cancelable by the landlord at any time prior to December 31, 2022 April 2022. Total lease costs were approximately $7,000 for the three March 31, 2022, Future undiscounted cash flows under this lease are: 2022 19,240 2023 33,974 2024 34,993 Total 88,207 Discount factor (12,151 ) Lease liability 76,056 Current lease liability (20,826 ) Non-current lease liability $ 55,230 In February 2022 March 2027. March 31, 2022 April 1, 2022; not March 31, 2022. not |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 3 Months Ended |
Mar. 31, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 8 Subsequent Events Effective April 29, 2022, April 11, 2022 On April 22, 2022, ten three The other receivable in the amount of $64,000 was received subsequent to March 31, 2022. As of May 15, 2022, May 13, 2022. May 18, 2022. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Liquidity, Policy [Policy Text Block] | Liquidity Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, and executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In mid- 2019, April 2021 2021, 2020 2019, December 2021, March 31, 2022, April 29, 2022. We have incurred, and continue to incur, recurring losses and negative cash flows. As of March 31, 2022, May 6, 2022, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. As a result of the closing of the private placement for proceeds of $3,500,000 on April 29, 2022, one |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, they do not December 31, 2021, not may not 10 December 31, 2021. The consolidated financial statements include the accounts of the Company and its wholly owned, controlled, and inactive subsidiary Aldagen, Inc. (“Aldagen”). All significant inter-company accounts and transactions are eliminated in consolidation |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Credit Concentration We had no April 2019 three March 31, 2022 2021 May 2022. Historically, we used single suppliers for several components of the Aurix® product line. We outsource the manufacturing of various product components to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is no one not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents We consider all highly liquid instruments purchased with an original maturity of three |
Receivable [Policy Text Block] | Accounts Receivables, net We expect to generate accounts receivables from the sale of our products. We will provide for an allowance against receivables for estimated losses that may not March 31, 2022 2021 no |
Other Receivables [Policy Text Block] | Other Receivables The other receivable at March 31, 2022 March 31, 2022. |
Inventory, Policy [Policy Text Block] | Inventory, net Our inventory is produced by third first first 18 two As of March 31, 2022, We will provide for an allowance against inventory for estimated losses that may |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment is stated at cost less accumulated depreciation and amortization. Assets are depreciated, using the straight-line method, over their estimated useful life ranging from one six one three April 2022. March 31, 2022, March 2022 |
Lessee, Leases [Policy Text Block] | Leases At the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby the Company (i) does not 12 |
Revenue [Policy Text Block] | Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not not not As more fully described above, we had no revenues in the three March 31, 2022 2021. |
Share-Based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The fair value of employee stock options is measured at the date of grant. Expected volatilities are based on the equally weighted average historical volatility from five three March 31, 2022 2021 2022 2021 Risk free rate 1.65 % 0.33 % Weighted average expected years until exercise 5-6 5 Expected stock volatility 100 % 100 % Dividend yield - - The Company elected to account for forfeitures of stock-based awards as they occur. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. Tax rate changes are reflected in income during the period such changes are enacted. We measure our deferred tax assets and liabilities using the enacted tax rates that we believe will apply in the years in which the temporary differences are expected to be recovered or paid. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not not The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no 2022 2021. |
Earnings Per Share, Policy [Policy Text Block] | Basic and Diluted Earnings (Loss) per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “treasury method” or “two class method.” Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method. Because none All of the Company’s outstanding stock options and warrants were considered anti-dilutive for the three March 31, 2022 2021. Three months ended March 31, 2022 Three months ended March 31, 2021 Shares underlying: Common stock options 2,536,667 1,355,001 Stock purchase warrants 233,333 13,278,794 2,770,000 14,633,795 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In August 2020, 2020 06 December 15, 2023, We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not |
Note 3 - Liquidity and Summar_2
Note 3 - Liquidity and Summary of Significant Accounting Principles (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2022 2021 Risk free rate 1.65 % 0.33 % Weighted average expected years until exercise 5-6 5 Expected stock volatility 100 % 100 % Dividend yield - - |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three months ended March 31, 2022 Three months ended March 31, 2021 Shares underlying: Common stock options 2,536,667 1,355,001 Stock purchase warrants 233,333 13,278,794 2,770,000 14,633,795 |
Note 4 - Property and Equipme_2
Note 4 - Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | March 31, 2022 December 31, 2021 Medical equipment $ 387,665 $ 387,665 Office equipment 3,243 - Warehouse/production equipment 8,605 - 399,513 387,665 Less accumulated depreciation and amortization (387,665 ) (387,665 ) Property and equipment, net $ 11,848 $ - |
Note 5 - Stock Purchase Warra_2
Note 5 - Stock Purchase Warrants (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Description March 31, 2022 March 31, 2021 May 2016 warrants - 6,180,000 2018 Convertible Notes warrants 233,333 233,333 2020 Replacement warrants - 3,977,961 2020 Compensatory warrants - 2,887,500 Total 233,333 13,278,794 |
Note 6 - Equity and Stock-bas_2
Note 6 - Equity and Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Stock Options 2016 Omnibus Plan Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at January 1, 2022 1,355,001 $ 0.52 3.90 Granted 1,181,666 $ 0.69 10.00 Exercised - $ - - Forfeited or expired - $ - - Outstanding at March 31, 2022 2,536,667 $ 0.60 6.58 Exercisable at March 31, 2022 2,103,334 $ 0.57 5.89 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2022 19,240 2023 33,974 2024 34,993 Total 88,207 Discount factor (12,151 ) Lease liability 76,056 Current lease liability (20,826 ) Non-current lease liability $ 55,230 |
Note 2 - Recapitalization (Deta
Note 2 - Recapitalization (Details Textual) - USD ($) | Feb. 05, 2020 | Dec. 10, 2019 | Sep. 17, 2018 | Dec. 31, 2021 | Oct. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2022 | Mar. 31, 2021 | Sep. 30, 2019 | Dec. 31, 2020 | Nov. 30, 2021 | Nov. 30, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 487,500 | |||||||||||
Proceeds from Issuance of Common Stock | $ 195,000 | |||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.40 | |||||||||||
Share-based Payment Arrangement, Expense | $ 6,430 | $ 0 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 233,333 | 13,278,794 | ||||||||||
Three Individuals [Member] | ||||||||||||
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture (in shares) | 962,500 | |||||||||||
Share-based Payment Arrangement, Expense | $ 333,628 | |||||||||||
Series A Preferred Stock Converted into Common Stock [Member] | ||||||||||||
Conversion of Stock, Shares Issued (in shares) | 2,700,000 | |||||||||||
Conversion of the 2018 Convertible Notes into Common Stock [Member] | ||||||||||||
Repayments of Convertible Debt | $ 350,000 | |||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 350,000 | |||||||||||
Conversion of the 2019 Senior Secured Notes into Common Stock [Member] | ||||||||||||
Debt Conversion, Original Debt, Amount | $ 305,000 | |||||||||||
Debt Conversion, Original Debt, Accrued Interest, Amount | $ 30,400 | |||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 838,487 | |||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.40 | |||||||||||
Warrants Issued with the 2018 Convertible Notes [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 466,666 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.15 | |||||||||||
Class of Warrant or Right, Outstanding (in shares) | 233,333 | 233,333 | ||||||||||
Warrants Issued with the 2018 Convertible Notes [Member] | Auctus Fund, LLC [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 233,333 | |||||||||||
Warrants Issued with the 2018 Convertible Notes [Member] | EMA Financial, LLC [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 233,333 | |||||||||||
Warrants Issued with 2019 Senior Secured Notes [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 457,500 | |||||||||||
Warrants Issued to Investors [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,977,961 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.40 | |||||||||||
Warrants Issued to Three Individuals [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,887,500 | |||||||||||
Modified Warrants [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,865,461 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.20 | $ 0.20 | $ 0.40 | $ 0.40 | ||||||||
Share-based Payment Arrangement, Expense | $ 13,936 | |||||||||||
Class of Warrant or Right, Outstanding (in shares) | 6,865,461 | |||||||||||
Warrant Modification, Amount | $ 795,592 | |||||||||||
The 2018 Convertible Notes [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||
Debt Instrument, Face Amount | $ 205,000 | |||||||||||
Proceeds from Convertible Debt | $ 315,800 | |||||||||||
Payments of Debt Issuance Costs | $ 34,200 | |||||||||||
Debt Instrument, Term (Month) | 9 months | |||||||||||
Debt Instrument, Convertible, Period After Date of Issuance (Month) | 6 months | |||||||||||
Debt Instrument, Convertible, Conversion Price, Percentage Discount of Common Stock Trading Price | 40.00% | |||||||||||
Debt Instrument, Amendment Fee | $ 69,000 | |||||||||||
Debt Instrument, Amendment Fee, Percent of Face Value | 20.00% | |||||||||||
Debt Instrument, Increase (Decrease) in Principal of Each Note | $ 30,000 | |||||||||||
Repayments of Convertible Debt | $ 220,000 | |||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 246,000 | |||||||||||
The 2018 Convertible Notes [Member] | Auctus Fund, LLC [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 175,000 | |||||||||||
The 2018 Convertible Notes [Member] | EMA Financial, LLC [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 175,000 | |||||||||||
The 2019 Senior Secured Notes [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||
Debt Instrument, Face Amount | $ 305,000 | |||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 89,776 | |||||||||||
Proceeds from Issuance of Senior Long-term Debt | $ 220,000 |
Note 3 - Liquidity and Summar_3
Note 3 - Liquidity and Summary of Significant Accounting Principles (Details Textual) - USD ($) | Apr. 29, 2022 | May 11, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | May 06, 2022 |
Net Cash Provided by (Used in) Financing Activities, Total | $ 0 | $ 0 | $ 1,900,000 | |||
Retained Earnings (Accumulated Deficit), Total | (23,968,449) | (23,593,069) | ||||
Cash and Cash Equivalents, at Carrying Value, Total | 665,391 | $ 1,414,569 | ||||
Accounts Receivable, after Allowance for Credit Loss, Total | 0 | 0 | ||||
Revenue from Contract with Customer, Including Assessed Tax | $ 0 | $ 0 | ||||
Minimum [Member] | ||||||
Property, Plant and Equipment, Useful Life (Year) | 1 year | |||||
Minimum [Member] | Leasehold Improvements [Member] | ||||||
Property, Plant and Equipment, Useful Life (Year) | 1 year | |||||
Maximum [Member] | ||||||
Property, Plant and Equipment, Useful Life (Year) | 6 years | |||||
Maximum [Member] | Leasehold Improvements [Member] | ||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |||||
Subsequent Event [Member] | ||||||
Proceeds from Issuance of Private Placement | $ 3,500,000 | $ 3,550,000,000,000 | ||||
Cash and Cash Equivalents, at Carrying Value, Total | $ 3,800,000 |
Note 3 - Liquidity and Summar_4
Note 3 - Liquidity and Summary of Significant Accounting Principles - Summary Stock Option Valuation Assumptions (Details) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Risk free rate | 1.65% | 0.33% |
Weighted average expected years until exercise (Year) | 5 years | |
Expected stock volatility | 100.00% | 100.00% |
Dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Weighted average expected years until exercise (Year) | 5 years | |
Maximum [Member] | ||
Weighted average expected years until exercise (Year) | 6 years |
Note 3 - Liquidity and Summar_5
Note 3 - Liquidity and Summary of Significant Accounting Principles - Anti-dilutive Securities Excluded From the Computation of Diluted Earnings (Loss) Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Anti-dilutive securities (in shares) | 2,770,000 | 14,633,795 |
Share-Based Payment Arrangement, Option [Member] | ||
Anti-dilutive securities (in shares) | 2,536,667 | 1,355,001 |
Warrant [Member] | ||
Anti-dilutive securities (in shares) | 233,333 | 13,278,794 |
Note 4 - Property and Equipme_3
Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Depreciation, Total | $ 0 | $ 0 |
Asset Impairment Charges, Total | $ 0 | $ 0 |
Note 4 - Property and Equipme_4
Note 4 - Property and Equipment - Property and Equipment, Net (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Property, plant, and equipment, gross | $ 399,513 | $ 387,665 |
Less accumulated depreciation and amortization | (387,665) | (387,665) |
Property and equipment, net | 11,848 | 0 |
Medical Equipment [Member] | ||
Property, plant, and equipment, gross | 387,665 | 387,665 |
Office Equipment [Member] | ||
Property, plant, and equipment, gross | 3,243 | 0 |
Warehouse and Production Equipment [Member] | ||
Property, plant, and equipment, gross | $ 8,605 | $ 0 |
Note 5 - Stock Purchase Warra_3
Note 5 - Stock Purchase Warrants (Details Textual) - USD ($) | 3 Months Ended | 12 Months Ended | |||||||
Mar. 31, 2022 | Dec. 31, 2021 | Nov. 30, 2021 | Dec. 31, 2020 | Nov. 30, 2020 | Oct. 31, 2020 | Dec. 31, 2019 | Sep. 17, 2018 | May 31, 2016 | |
May 2016 Warrants [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,180,000 | ||||||||
May 2016 Warrants [Member] | Minimum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.50 | ||||||||
May 2016 Warrants [Member] | Maximum [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.75 | ||||||||
Warrants Issued with the 2018 Convertible Notes [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 466,666 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.15 | ||||||||
Class of Warrant or Right, Outstanding, Weighted Average Remaining Contractual Term (Year) | 1 year 6 months | ||||||||
Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value | $ 0 | ||||||||
Warrants Issued with 2019 Senior Secured Notes Upon Conversion [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,977,971 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.40 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||
Warrants Issued to Employees [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,887,500 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.40 | ||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||
Modified Warrants [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,865,461 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.20 | $ 0.40 | $ 0.20 | $ 0.40 | |||||
Proceeds from Warrant Exercises | $ 1,373,092 |
Note 5 - Stock Purchase Warra_4
Note 5 - Stock Purchase Warrants - Outstanding Stock Purchase Warrants (Details) - shares | Mar. 31, 2022 | Mar. 31, 2021 |
Outstanding warrants (in shares) | 233,333 | 13,278,794 |
May 2016 Warrants [Member] | ||
Outstanding warrants (in shares) | 0 | 6,180,000 |
Warrants Issued with the 2018 Convertible Notes [Member] | ||
Outstanding warrants (in shares) | 233,333 | 233,333 |
The 2020 Replacement Warrants [Member] | ||
Outstanding warrants (in shares) | 0 | 3,977,961 |
The 2020 Compensatory Warrants [Member] | ||
Outstanding warrants (in shares) | 0 | 2,887,500 |
Note 6 - Equity and Stock-bas_3
Note 6 - Equity and Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | ||||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 04, 2022 | Dec. 31, 2021 | Aug. 04, 2016 | |
Authorized Shares, Common and Preferred (in shares) | 101,000,000 | ||||
Common Stock, Shares Authorized (in shares) | 100,000,000 | 100,000,000 | |||
Preferred Stock, Shares Authorized (in shares) | 1,000,000 | ||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.0001 | ||||
Issuance of Options to Settle Accrued Compensation Liabilities | $ 103,333 | $ 0 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares) | 525,000 | ||||
Share-based Payment Arrangement, Expense | $ 6,430 | $ 0 | |||
The 2016 Omnibus Plan [Member] | |||||
Evergreen Provision, Increase in Number of Shares Authorized Calculation, Percentage Amount of Prior Year's Reserved Shares | 6.00% | ||||
Evergreen Provision, Maximum Limit of Increase to Authorized Shares (in shares) | 1,000,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 4,250,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 1,181,666 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | ||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 6,200 | ||||
The 2016 Omnibus Plan [Member] | Additional Paid-in Capital [Member] | |||||
Issuance of Options to Settle Accrued Compensation Liabilities | $ 103,333 | ||||
The 2016 Omnibus Plan [Member] | Senior Management and Board of Directors [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 206,666 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value | $ 3,000 | ||||
The 2016 Omnibus Plan [Member] | Management, Board of Directors, Service Provider [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 450,000 | ||||
The 2016 Omnibus Plan [Member] | Employees [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 525,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years |
Note 6 - Equity and Stock-bas_4
Note 6 - Equity and Stock-based Compensation - Stock Option Activity (Details) - The 2016 Omnibus Plan [Member] - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Shares outstanding (in shares) | 1,355,001 | |
Shares outstanding, weighted-average exercise price (in dollars per share) | $ 0.52 | |
Shares outstanding, weighted-average remaining contractual term (Year) | 6 years 6 months 29 days | 3 years 10 months 24 days |
Shares granted (in shares) | 1,181,666 | |
Shares granted, weighted-average exercise price (in dollars per share) | $ 0.69 | |
Shares granted, weighted-average remaining contractual term (Year) | 10 years | |
Shares exercised (in shares) | 0 | |
Shares exercised, weighted-average exercise price (in dollars per share) | $ 0 | |
Shares forfeited or expired (in shares) | 0 | |
Shares forfeited or expired, weighted-average exercise price (in dollars per share) | $ 0 | |
Shares outstanding (in shares) | 2,536,667 | 1,355,001 |
Shares outstanding, weighted-average exercise price (in dollars per share) | $ 0.60 | $ 0.52 |
Shares exercisable (in shares) | 2,103,334 | |
Shares exercisable, weighted-average exercise price (in dollars per share) | $ 0.57 | |
Shares exercisable, weighted-average remaining contractual term (Year) | 5 years 10 months 20 days |
Note 7 - Commitments and Cont_3
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | 3 Months Ended | |||
Mar. 31, 2022 | Apr. 01, 2022 | Jan. 31, 2022 | Dec. 31, 2021 | |
Operating Lease, Right-of-Use Asset | $ 84,023 | $ 89,312 | $ 0 | |
Operating Lease, Weighted Average Discount Rate, Percent | 10.00% | |||
Operating Lease, Expense | $ 7,000 | |||
Lessee, Operating Lease, Liability, to be Paid, Total | 88,207 | |||
Operating Lease, Liability, Total | $ 76,056 | $ 89,312 | ||
Additional Commercial Operating Lease [Member] | Subsequent Event [Member] | ||||
Lessee, Operating Lease, Liability, to be Paid, Total | $ 423,000 |
Note 7 - Commitments and Cont_4
Note 7 - Commitments and Contingencies - Future Undiscounted Cash Flows (Details) - USD ($) | Mar. 31, 2022 | Jan. 31, 2022 | Dec. 31, 2021 |
2022 | $ 19,240 | ||
2023 | 33,974 | ||
2024 | 34,993 | ||
Total | 88,207 | ||
Discount factor | (12,151) | ||
Lease liability | 76,056 | $ 89,312 | |
Current lease liability | (20,826) | $ 0 | |
Non-current lease liability | $ 55,230 | $ 0 |
Note 8 - Subsequent Events (Det
Note 8 - Subsequent Events (Details Textual) - USD ($) | May 15, 2022 | Apr. 29, 2022 | Apr. 22, 2022 | May 11, 2022 | Oct. 31, 2020 |
Stock Issued During Period, Shares, New Issues (in shares) | 487,500 | ||||
Proceeds from Issuance of Common Stock | $ 195,000 | ||||
Subsequent Event [Member] | |||||
Proceeds from Issuance of Private Placement | $ 3,500,000 | $ 3,550,000,000,000 | |||
Increase (Decrease) in Other Receivables | $ 64,000 | ||||
Subsequent Event [Member] | Non-executive Employees [Member] | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 775,000 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 3 years | ||||
Subsequent Event [Member] | Non-executive Employees [Member] | Minimum [Member] | |||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.75 | ||||
Subsequent Event [Member] | Non-executive Employees [Member] | Maximum [Member] | |||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 1 | ||||
Private Placement [Member] | Subsequent Event [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,550,000 | ||||
Proceeds from Issuance of Private Placement | $ 3,550,000 | ||||
Stock Issuance Agreement, Number of Shares (in shares) | 4,000,000 | ||||
Securities Purchase Agreement [Member] | Subsequent Event [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 407,757 | ||||
Proceeds from Issuance of Common Stock | $ 407,757 |